Laboratorios Farmaceuticos Rovi, S.A. · BME:ROVI

Laboratorios Farmaceuticos Rovi — Investor Presentation (November 2021)

26 slides from Laboratorios Farmaceuticos Rovi's investor presentation, November 2021

  1. Slide 1: Creating Value for Investors Through Next Phase of Growth

    CREATING VALUE FOR INVESTORS THROUGH NEXT PHASE OF GROWTH NOVEMBER 2021

  2. Slide 2: Disclaimer

    DISCLAIMER This Presentation has been prepared by Laboratorios Farmacéuticos ROVI, S.A. (the “Company”) and comprises the slides for a presentation concerning the Company and its subsidiaries (the “Group”). For the purposes of this disclaimer, “Presentation” means this document, its contents or any

  3. Slide 3: Overview

    OVERVIEW MKT CAP (€M)1 Solid specialty pharma growth story coupled Revenue Madrid, with strong potential from the ISM® Platform 9M 20212 Spain +7.5x Company HQ 4.000 3,544 3.500 Leading • Unparalleled know-how of the Low Molecular Weight Heparin (“LMWH”) market. Proprietary 3.000 LMWH 38%5 2.500 • 2

  4. Slide 4: ROVI improves its ESG Rating in 2021

    ROVI improves its ESG Rating in 2021 2nd position out of 432 companies (in the sub-industry “pharmaceuticals”) Rovi has obtained an ESG Rating 2021 of 2.309 out of 13.573 Global Universe 18,4 (low risk between 10 and 20) 17 out of 896 Industry Group (biotech + laboratory equipment + pharma companies

  5. Slide 5: Key Company Highlights

    Key Company Highlights Well-balanced pan-European specialty pharma business with diversified growth drivers Unparalleled proprietary heparin franchise with strong European footprint Leading Spanish specialty pharma franchise High-value-added global CMO business with differentiated capabilities Propr

  6. Slide 6: Well-Balanced European Specialty Pharma Company with Three Diversified Growth Drivers

    Well-Balanced European Specialty Pharma Company with Three Diversified Growth Drivers Leading Proprietary Leading Spanish Specialty High-Value-Added CMO LMWH Franchise Pharma Franchise Services • Developed and successfully launched • Strong market leadership in Spain • One of the global leaders in p

  7. Slide 7: Bemiparin Hibor is ROVI's First Internally-Developed Flagship Heparin Product

    Bemiparin Hibor® is ROVI’s First Internally-Developed Flagship Heparin Product Unparalleled Know-How of the Heparin Market Bemiparin HIBOR® is the LMWH with the highest anti Xa/IIa ratio, which may lead to a higher antithrombotic activity without • ROVI has been engaged in the development of heparin

  8. Slide 8: Enoxaparin Global Market Represents an Untapped Opportunity for Becat

    Enoxaparin €2.6bn Global Market Represents an Untapped Opportunity to Be Explored with ROVI’s biosimilar Becat® European Market Represents an Attractive Well-Positioned for Long-Term Leadership Opportunity in LMWH • ROVI aims to become one of Europe’s top players in a €1.3bn • Enoxaparin (such as Cl

  9. Slide 9: Strong growth potential of Enoxaparin Biosimilar Becat

    Strong growth potential of Enoxaparin Biosimilar Becat® Well-Established Network to Minimize Time- Stage I of Commercial Strategy to-Market ROVI will directly market In the long-term, enoxaparin biosimilar Becat® biosimilars tend to reach Direct in 7 European countries… a… Approved in Marketed in 26

  10. Slide 10: Spanish Market Leadership Positions ROVI as the Partner of Choice

    Spanish Market Leadership Positions ROVI as the Partner of Choice for Global Pharma Players in Spain Our Strong Market Leadership in Spain… …allows us to be the Partner of Choice for Global Pharma Players in Spain Servier Presence in the Spanish market 2007 since 1946 Merck 2008 Well-known proprieta

  11. Slide 11: High-Value-Added Global CMO Services

    High-Value-Added Global CMO Services CMO Targets Customer-oriented business model Toll manufacturing sales High-value-added service with pre-filled increased 39% in 2020 and 187% syringes toll manufacturing in 9M 2021 Differentiated capabilities drive significant barriers to entry • ROVI expects the

  12. Slide 12: ROVI strengthens its collaboration with Moderna (1/2)

    ROVI strengthens its collaboration with Moderna (1/2) Fill-Finish manufacturing • Investment in 2 new lines for compounding, filling, automatic visual inspection and labeling at ROVI’s San Sebastián de los Reyes (Madrid) facility • These lines will more than double the number of vials for which ther

  13. Slide 13: ROVI strengthens its collaboration with Moderna (2/2)

    ROVI strengthens its collaboration with Moderna (2/2) Manufacture of the active substance • Installation of a new line in Granada • Production capacity equivalent to more than 100 million doses per year • Greater vertical integration of the vaccine production process • Supply to markets outside the

  14. Slide 14: ISM Platform opens up new avenues of growth for ROVI

    ISM® Platform opens up new avenues of growth for ROVI Overview • Internally-developed and patented innovative drug-release technology, ISM®, Key Company Highlights of ISM® Platform 1 which allows for the sustained release of compounds administered by injection 2 Pop PK model & Expected high • Based

  15. Slide 15: Risperidone ISM: Attractive Schizophrenia Market with Strong Growth Prospects

    Risperidone ISM®: Attractive Schizophrenia Market with Strong Growth Prospects Attractive Schizophrenia Market Solid Grounds for Success for a Risperidone LAI ● Chronic and progressive disease High treatment switching rate ● Affects 21m people worldwide with a relatively high lifetime prevalence1 LA

  16. Slide 16: Risperidone ISM: Fast Onset Long-Acting Injectable of Risperidone

    Risperidone ISM®: Fast Onset Long-Acting Injectable of Risperidone Superior Value Proposition When Strong Product Expected to Offer Superior Compared to Alternatives Characteristics • Ongoing monitoring of non- Fully adherence through regular INVEGA INVEGA interactions between patient and RISPERDAL

  17. Slide 17: European regulatory process - Where are we?

    European regulatory process - Where are we? Resume of regulatory process Day 1 Day 120 Day 180 Secondary Primary evaluation evaluation Validation (List of questions) (list of outstanding issues) Responses We are here Day 181 – 16/11/2021 Day 210 Day 237 Resume of the CHMP1 Positive Transmission to p

  18. Slide 18: Therapeutic Indication – Covering the Unmet Medical Need

    Therapeutic Indication – Covering the Unmet Medical Need Requested Therapeutic Indication to EMA Treatment of Schizophrenia in adults Risperidone ISM® would be the ONLY1 Long-Acting Injectable Antipsychotic that can be administered to unstable patients with severe or moderate psychotic symptoms suff

  19. Slide 19: USA regulatory process – Where are we?

    USA regulatory process – Where are we? The recommended follow-up phases with the FDA1 were On 24 September, 2021, ROVI covered: received a Complete Response ROVI submitted the dossier to the • Pre-IND2 FDA1 on November 24, 2020 Letter from the FDA with • IND2 outstanding questions on the • End of ph

  20. Slide 20: Letrozole ISM: Second ISM Candidate in Phase I Trial

    Letrozole ISM®: Second ISM® Candidate in Phase I Trial Overview Preliminary Phase I Results Hormone receptor-targeting drugs offer a unique opportunity to leverage ISM® technology. Aromatase Inhibitors (AI) Letrozole and Anastrozole are used in HR+ breast cancer as they Rapid and sustained estrogen

  21. Slide 21: Sound Financial Policy Supported by Strong Track Record

    Sound Financial Policy Supported by Strong Track Record Specialty Pharma ++ ISM® Platform = ROVI Group Total Revenues 1 R&D Revenues 5 Total Revenues 1&5 €m 276 304 382 421 92 €m €m 277 305 382 422 66 61 55 316 330 1,3 1,1 0,5 0,6 215 249 2017A 2018A 2019A 2020A 2017A 2018A 2019A 2020A 2017A 2018A 2

  22. Slide 22: 9M 2021 results (1/2)

    9M 2021 results (1/2) Specialty pharma business €m REVENUE EBITDA EBIT Prescription €256.6 +18% products 463.5 (+53%) 139.5 (+100%) 123.3 (+123%) Total Capex Net cash €283.3m Contrast Net profit €25.8 +17% agents 98.9 (+111%) 22.0 (30%) 74.4 +18% OTC & €0.9 +78% Other 2022 operating revenue guidance

  23. Slide 23: 9M 2021 results (2/2)

    9M 2021 results (2/2) Gross profit (€m) and gross margin (%) EBITDA (€m) and EBITDA margin (%) 57,6% 58,1% 60% 150 30,1% 40% 250 EBITDA Pre-R&D1 +86% 200 +52% 100 23,1% 30% €m 40% €158.6m €Mn 150 139,5 20% 266,8 100 50 175,4 20% 69,7 10% 50 0 0% 0 0% 9M 2020 9M 2021 9M 2020 9M 2021 EBITDA EBITDA mar

  24. Slide 24: Outlook 2022

    Outlook 2022 2022 operating revenue growth rate Mid-single-digit The key Growth levers in 2022 Specialty Pharma CMO Bemiparin Spare capacity in the manufacturing Biosimilar of Enoxaparin plants Launches such as Neparvis® New customers to be acquired and Volutsa® Agreement with Moderna Existing portf

  25. Slide 25: 2023 long term guidance expected to be achieved in 2021

    2023 long term guidance expected to be achieved in 2021 LT indicative 2018 2021 guidance 2023 Operating X2 Expected to be €303.2Mn €588Mn - €609Mn revenues €606.4Mn achieved in 2021 €158.6Mn in 9M 2021 X2.5 Already achieved EBITDA pre-R&D €63.0Mn EBITDA pre-R&D €157.5Mn in 9M 2021 Next phase of grow

  26. Slide 26: For further information, please contact

    For further information, please contact: Juan López-Belmonte Chairman and Chief Executive Officer +34 91 3756235 www.rovi.es Javier López-Belmonte Vicepresident and Chief Financial Officer +34 91 3756266 www.rovi.es Marta Campos Head of Investor Relations +34 91 2444422 [email protected] www.rovi.es A

Laboratorios Farmacéuticos ROVI — Investor Presentation (November 2021) on 6ix